Biohaven Ltd. (BHVN) Revenue, Margins & Financial Statements

Revenue growth, profit margins, cash flow, debt, sourced from SEC 10-K / 10-Q filings
Summary

Biohaven Ltd. (BHVN) reported — in revenue over the most recent fiscal year on record. Growth has been not enough data. Free cash flow ran 83% of net income in the latest year. The balance sheet holds $319.14M more in cash & investments than debt. Share count grew 31.2% over the past year, some dilution.

Profitability
Moderate
Operating margin is roughly steady, neither expanding nor compressing sharply.
Cash Generation
Weak
Free cash flow was negative in the most recent year.
Balance Sheet
Strong
Holds more cash than debt, with healthy short-term liquidity.
Shareholder Returns
Diluting
Share count grew 31.2% year over year.
Is Revenue Growth Accelerating or Slowing?

Biohaven Ltd.'s revenue for the fiscal year ended Dec 2025 was . Is growth accelerating, stable, slowing, or contracting? See the quarterly beat/miss history →

Trend (annual)
Not enough data
Fiscal Year EndedRevenue Growth
Dec 2025
Dec 2024
Dec 2023
Dec 2022
Dec 2021

"Accelerating" / "Slowing" means each of the last 3 years' growth rates moved consistently in that direction, not a subjective call.

Profit Margins
Revenue growth
Net income growth
+12.7%
Free cash flow growth
-4.0%
Gross margin
Roughly stable
Operating margin
Roughly stable
BHVN vs. Its Healthcare Peers

Compared against 8 other Healthcare stocks tracked on this site, not the whole market, and small enough that this is directional context, not a definitive benchmark.

Why did EPS grow?

EPS +26.1% year over year. A rough breakdown of what drove it (approximate, since EPS is roughly net income divided by share count):

Revenue growth
Margin expansion (profit grew faster than sales)
Share buybacks (fewer shares to divide profit across)
Cash Flow & Free Cash Flow

Accounting profit is not the same as cash in the bank. Here's how BHVN converts revenue into real cash.

Cash conversion (OCF / Net Income)
82%
FCF conversion (FCF / Net Income)
83%
Capital intensity (CapEx / OCF)
-0%
Balance Sheet & Debt
Net cash
$319.14M
Working capital
$252.40M
Quick ratio
3.18
Cash Runway

BHVN used more cash in operations than it generated in the most recent year. At that burn rate:

Estimated runway
6 months
$319.14M in cash & investments divided by approximately $50.79M/month burn rate
Share Dilution & Buybacks
Share count, 1yr change
+31.2%
Share count, 3yr change
+94.7%
Dilution warning: share count grew +31.2% year over year.
Capital Allocation

How BHVN deployed cash in the most recent year, across its actual cash-flow-statement uses.

Capital Expenditures$715.0K
Financial Red Flags & Strengths

Objective, rule-based checks against the figures above, not a subjective rating.

Watch items
Free cash flow was negative in the most recent year.
Share count grew 31.2% year over year, meaningful dilution.
Strengths
Holds more cash & investments than debt (net cash position).
Year in Review
Fiscal Year EndedRevenue GrowthMargin ChangeFCF Growth
Dec 2025-4.0%
Dec 2024-75.2%
Dec 2023-10.2%
Dec 2022-107.0%
Dec 2021-90.5%
Frequently asked questions
Is BHVN's revenue growing?

Biohaven Ltd.'s revenue growth has been not enough data.

Are BHVN's profit margins improving or declining?

Operating margin has been roughly stable recently. It is currently in the middle of the last — years.

Is BHVN's reported profit backed by real cash?

Operating cash flow ran +82% of net income, and free cash flow ran +83% of net income, in the most recent year. Cash generation roughly tracks reported profit.

Does BHVN have more cash than debt?

Yes, BHVN holds $319.14M more in cash & short-term investments than its total debt.

Is BHVN diluting shareholders or buying back stock?

BHVN's share count grew +31.2% over the past year, existing shareholders were diluted.

What are the biggest financial red flags for BHVN right now?

Free cash flow was negative in the most recent year. Share count grew 31.2% year over year, meaningful dilution.

Full statements

Every line item as reported, with the annual/quarterly toggle and ratio table.

Line itemDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021
Research & Development$635.07M$795.87M$373.28M$437.07M$181.49M
General & Administrative$110.31M$89.24M$62.77M$130.86M$37.41M
Total Operating Expenses$745.38M$885.11M$436.05M$567.93M$218.90M
Operating Income-$745.38M-$885.11M-$436.05M-$567.93M-$218.90M
Nonoperating Income (Expense)$8.00M$39.42M$26.50M-$1.91M$6.47M
Pretax Income-$737.38M-$845.69M-$409.55M-$569.84M-$212.43M
Income Tax Expense$1.44M$735.0K-$1.38M$438.0K$1.37M
Net Income-$738.82M-$846.42M-$408.17M-$570.28M-$213.80M
EPS (Basic)$-6.86$-9.28$-5.73$-12.75$-5.43
EPS (Diluted)$-6.86$-9.28$-5.73$-12.75$-5.43
Weighted Avg Shares (Basic)107.62M91.23M71.20M44.74M39.38M
Weighted Avg Shares (Diluted)107.62M91.23M71.20M44.74M39.38M

Sourced from SEC filings (10-K / 10-Q). Figures not separately reported by the company are shown as —, not estimated. Quarterly "derived Q4" values are calculated as the full fiscal year total minus the three reported quarters.

Key ratios

Computed from the annual figures above, most recent first.

RatioDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020
Gross Margin
Operating Margin
Net Margin
Return on Equity-1418.8%-199.9%-95.4%-105.8%-616.3%-707.2%
Current Ratio3.183.497.986.522.26
Debt / Equity0.000.000.000.000.000.00
Free Cash Flow-$610.15M-$586.50M-$334.77M-$303.76M-$146.78M-$77.05M
Figures are sourced directly from BHVN's SEC filings (10-K annual reports and 10-Q quarterly reports) via XBRL data. Classifications above (trend labels, snapshot categories, red flags) use fixed, stated rules applied to these figures, not a subjective or predictive score. This is historical financial data, not investment advice. Read disclaimer →